Candel Therapeutics, Inc. (CADL)
Largest Insider Buys in Sector
CADL Stock Price History Chart
CADL Stock Performance
About Candel Therapeutics, Inc.
Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. The company develops CAN-2409, which is in Phase II clinical trails for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma. It also develops CAN-3110, which is in Phase I clinical trials for the treatment of …
Insider Activity of Candel Therapeutics, Inc.
Over the last 12 months, insiders at Candel Therapeutics, Inc. have bought $7.5M and sold $1.82M worth of Candel Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at Candel Therapeutics, Inc. have bought $7.46M and sold $1.82M worth of stock each year.
Highest buying activity among insiders over the last 12 months: Manning Paul B (director) — $37.5M.
The last purchase of 1,250,000 shares for transaction amount of $7.5M was made by Manning Paul B (director) on 2024‑12‑16.
List of Insider Buy and Sell Transactions, Candel Therapeutics, Inc.
| 2024-12-16 | director | 1.25M 3.786% | $6.00 | $7.5M | +24.59% | |||
| 2024-11-29 | Sale | Chief Executive Officer | 48,847 0.1456% | $4.56 | $222,527 | +9.13% | ||
| 2024-11-29 | Sale | Chief Scientific Officer | 22,081 0.0658% | $4.56 | $100,592 | +9.13% | ||
| 2024-11-29 | Sale | Chief Technology Officer | 20,392 0.0608% | $4.56 | $92,898 | +9.13% | ||
| 2024-11-29 | Sale | Chief Medical Officer | 13,935 0.0415% | $4.56 | $63,482 | +9.13% | ||
| 2024-10-15 | Sale | 10 percent owner | 10,412 0.0279% | $6.03 | $62,784 | -14.79% | ||
| 2024-10-14 | Sale | 10 percent owner | 15,000 0.0401% | $6.02 | $90,300 | -15.17% | ||
| 2024-10-11 | Sale | 10 percent owner | 15,000 0.0403% | $6.05 | $90,750 | -15.03% | ||
| 2024-10-03 | Sale | 10 percent owner | 1,800 0.0055% | $6.85 | $12,330 | -21.31% | ||
| 2024-10-02 | Sale | 10 percent owner | 26,988 0.083% | $6.92 | $186,757 | -22.47% | ||
| 2024-10-01 | Sale | 10 percent owner | 6,214 0.0194% | $7.01 | $43,555 | -24.21% | ||
| 2024-07-17 | Sale | Chief Executive Officer | 22,528 0.0746% | $6.47 | $145,815 | -9.44% | ||
| 2024-07-17 | Sale | Chief Scientific Officer | 14,051 0.0465% | $6.47 | $90,947 | -9.44% | ||
| 2024-07-17 | Sale | Chief Technology Officer | 14,851 0.0492% | $6.47 | $96,125 | -9.44% | ||
| 2024-07-17 | Sale | Chief Medical Officer | 10,875 0.036% | $6.47 | $70,390 | -9.44% | ||
| 2024-07-17 | Sale | See Remarks | 9,884 0.0327% | $6.47 | $63,975 | -9.44% | ||
| 2024-07-11 | Sale | Chief Executive Officer | 20,293 0.0713% | $5.97 | $121,218 | 0.00% | ||
| 2024-07-11 | Sale | Chief Scientific Officer | 12,645 0.0445% | $5.97 | $75,534 | 0.00% | ||
| 2024-07-11 | Sale | Chief Technology Officer | 13,330 0.0469% | $5.97 | $79,625 | 0.00% | ||
| 2024-07-11 | Sale | Chief Medical Officer | 9,769 0.0343% | $5.97 | $58,354 | 0.00% |
Insider Historical Profitability
| Manning Paul B | director | 1303752 2.9314% | $8.75 | 3 | 0 | <0.0001% |
| Tak Paul Peter | Chief Executive Officer | 294788 0.6628% | $8.75 | 3 | 3 | <0.0001% |
| Barone Francesca | Chief Scientific Officer | 137880 0.31% | $8.75 | 1 | 3 | <0.0001% |
| Tyagarajan Seshu | Chief Technology Officer | 125657 0.2825% | $8.75 | 2 | 3 | <0.0001% |
| Martell Christopher | director | 152000 0.3418% | $8.75 | 3 | 0 | <0.0001% |
Institutional Investor Ownership
| Northpond Partners LLC | $3.06M | 6.5 | 1.94M | 0% | +$0 | 0.07 | |
| Sands Capital Ventures LLC | $1.28M | 2.73 | 811,737 | 0% | +$0 | 0.31 | |
| The Vanguard Group | $855,246.00 | 1.82 | 541,295 | +27.14% | +$182,562.66 | <0.0001 | |
| Geode Capital Management | $230,256.00 | 0.49 | 145,706 | +4.63% | +$10,197.53 | <0.0001 | |
| Bridgeway Capital Management | $130,500.00 | 0.28 | 82,595 | -37.71% | -$78,999.94 | <0.01 |